Navigation Links
Inimex Announces Appointment of New CEO
Date:11/23/2009

BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO.

Abrams brings more than 25 years of drug discovery and development experience to Inimex. He is a co-inventor of the nuclear medicine imaging agent, Cardiolite, and worked from 1984 to 1996 at Johnson Matthey, plc where he was Manager, Biomedical Research Worldwide. In 1996, Abrams led the establishment of AnorMED in Langley, BC and was President and CEO from 1996 to 2006. AnorMED discovered and developed Mozobil, a drug for improving stem cell collection in cancer patients undergoing stem cell transplantation. AnorMED was acquired by Genzyme Corp. for $580M in 2006, and Mozobil was FDA approved in December 2008. Abrams is actively involved in the Vancouver biotech community as a member of public, private and not-for-profit boards.

"We are thrilled that Dr. Abrams has joined the Inimex executive team," said Robert Fildes, Chairman of the Board of Inimex. "His experience and leadership qualities will be a great asset to Inimex as the company makes the transition from a pre-clinical company to one with a drug candidate advancing through clinical development."

Dr. John R. North, who led the early development of Inimex' drug technology, serving as EVP of R&D in 2004 and then President and Chief Executive Officer from 2005 to 2009, will assume a new role as Chief Operating Officer.

"In this era of increasing antibiotic resistance and emerging infectious diseases, new strategies for dealing with these problems are very much in demand. Inimex, with its Innate Defense Regulator technology, is in a great position to address these needs," said Abrams.

    About Inimex Pharmaceuticals
    ----------------------------

Inimex Pharmaceuticals Inc. is a privately held biopharmaceutical company dedicated to the discovery and development of new medicines based on the selective modulation of the innate immune response. With its first drug candidate, IMX942, having completed Phase 1 clinical studies in healthy volunteers, Inimex' products show promise for the safe and effective treatment of a broad spectrum of serious unmet medical needs in infectious disease and inflammatory disorders.

For more information, please visit www.inimexpharma.com.

SOURCE Inimex Pharmaceuticals Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... Charm Sciences, Inc. is pleased to announce that its Charm ... appropriate as a screening test at dairies and farms for raw commingled cow milk. ... Charm EZ Lite system. These systems are a combination incubator and reader in one. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found ... latest book, Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, ... effect on men. ”The logical next step, in my estimation, was to scientifically track ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/20/2017)... Parsippany, NJ (PRWEB) , ... June 20, 2017 , ... ... OHAUS makes the transition from being a trusted supplier in the weighing industry, to ... including cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):